Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or (MPP), technology, with an initial focus on the treatment of eye diseases.
Our MPPs are selectively-sized nanoparticles and have proprietary coatings. We believe that these two key attributes enable even distribution of drug particles on mucosal surfaces and significantly increase drug delivery to target tissues by enhancing mobility of drug particles through mucus and preventing drug particles from becoming trapped and eliminated by mucus.Read More »
Data provided by Nasdaq. Minimum 15 minutes delayed.
|Jan 7, 2019|
Kala Pharmaceuticals Announces the Launch of INVELTYS™ and the Hiring of a Specialty Ophthalmology Sales Organization
|Jan 2, 2019|
Kala Pharmaceuticals to Present at 37th Annual J.P. Morgan Healthcare Conference
|Dec 26, 2018|
Kala Pharmaceuticals Announces New Drug Application for KPI-121 0.25% for Dry Eye Disease Has Been Accepted for Review by the U.S. Food and Drug Administration
|There are currently no events scheduled.|